Sunovion Knocks Out 5 Patents In Mylan's Brovana Suit

Law360, New York (March 2, 2012, 6:58 PM EST) -- Mylan Inc. on Friday vowed to appeal after a New York federal judge ruled that five patents asserted against Sunovion Pharmaceuticals Inc. in a suit over the chronic pulmonary obstructive disease drug Brovana were invalid, and limited potential damages on the two other patents-in-suit.

U.S. District Judge John Koeltl signed off on a 43-page opinion and order granting a motion for partial summary judgment from Dainippon Sumitomo Pharma Co. Ltd. unit Sunovion, concluding that the second of two families of patents being asserted by Mylan and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.